MiR-486-5p Downregulation Marks an Early Event in Colorectal Carcinogenesis

被引:8
|
作者
Kelley, Katherine A. [1 ]
Wieghard, Nicole [1 ]
Chin, Yuki [1 ]
Potter, Amiee [2 ]
Mori, Motomi [2 ,3 ]
Wong, Melissa H. [3 ,4 ]
Chin, Koei [5 ]
Tsikitis, V. Liana [1 ]
机构
[1] Oregon Hlth & Sci Univ, Dept Gen Surg, Portland, OR 97239 USA
[2] Portland State Univ, Sch Publ Hlth, Pregon Hlth & Sci Univ, Portland, OR 97207 USA
[3] Oregon Hlth & Sci Univ, Knight Canc Inst Biostat, Portland, OR 97239 USA
[4] Oregon Hlth & Sci Univ, Dept Cell Dev & Canc Biol, Portland, OR 97239 USA
[5] Oregon Hlth & Sci Univ, Ctr Spatial Syst Biomed, Portland, OR 97239 USA
关键词
Colorectal carcinogenesis; Early and late stages of disease; Metastasis; MicroRNA; MicroRNA dysregulation pathways; TUMOR-GROWTH; CANCER; EXPRESSION; METASTASIS; CARCINOMA;
D O I
10.1097/DCR.0000000000001192
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND: MicroRNAs are dysregulated in colorectal cancer and subsets correlated with advanced tumor stage and metastasis. Data are lacking on microRNA dysregulation from early to late-stage disease. OBJECTIVE: The purpose of this study was to identify a microRNA signature associated with the primary tumor and metastatic site in stage IV disease and to examine whether the signature is evident in earlier stages. DESIGN: A microRNA profile was generated and then explored in normal colon tissue (n = 5), early stage (stage I and II; n = 10), and late-stage (stage III and IV; n = 14) colorectal primary tumors via polymerase chain reaction to delineate molecular events that may promote colorectal carcinogenesis. SETTING: Genome-wide microRNA expression profiling was performed. PATIENTS: A total of 14 patient-matched stage IV primary colorectal cancer tumors and corresponding liver metastases were included. MAIN OUTCOME MEASURES: MicroRNA array technology was used to identify microRNA expression-predictive metastatic potential in the primary tumor. RESULTS: A distinct 9-member signature group of microRNAs was concurrent in stage IV primary colorectal cancer and their corresponding liver metastases, when compared with surrounding unaffected colon and liver tissue (microRNA-18b, microRNA-93, microRNA-182, microRNA-183, microRNA21, microRNA-486-5p, microRNA-500a, microRNA-552, and microRNA-941). Of the microRNA panel, only microRNA486-5p was differentially expressed in early stage colorectal cancer samples compared with normal tissue (p = 0.001) and additionally differentially expressed between late-stage colorectal cancer samples and normal tissue (p < 0.01). LIMITATIONS: Our microRNA profile was generated in a small subset of patients and will require validation in more samples. CONCLUSIONS: We identified a distinct microRNA signature in primary colon and matched metastatic disease. On additional investigation, 1 microRNA was differentially expressed in both early and late-stage cancer patient samples, and it may herald an early event in colorectal carcinogenesis. This study warrants additional investigation with a larger patient cohort to better understand the effect of microRNAs in carcinogenesis. See Video Abstract at http://links.lww.com/DCR/A723.
引用
下载
收藏
页码:1290 / 1296
页数:7
相关论文
共 50 条
  • [1] Downregulation of KIAA1199 by miR-486-5p suppresses tumorigenesis in lung cancer
    Wang, Anqi
    Zhu, Jianjie
    Li, Juan
    Du, Wenwen
    Zhang, Yang
    Cai, Tingting
    Liu, Ting
    Fu, Yulong
    Zeng, Yuanyuan
    Liu, Zeyi
    Huang, Jian-an
    CANCER MEDICINE, 2020, 9 (15): : 5570 - 5586
  • [2] Downregulation of miR-486-5p in papillary thyroid carcinoma tissue: A study based on microarray and miRNA sequencing
    Wen, Dong-Yue
    Pan, Deng-Hua
    Lin, Peng
    Mo, Qiu-Yan
    Wei, Yun-Peng
    Luo, Yi-Huan
    Chen, Gang
    He, Yun
    Chen, Jun-Qiang
    Yang, Hong
    MOLECULAR MEDICINE REPORTS, 2018, 18 (03) : 2631 - 2642
  • [3] Methylation detection of circulating tumor cell miR-486-5p/miR-34c-5p in the progression of colorectal cancer
    Li, Guolei
    Hu, Xuhua
    Wang, Guiying
    Geng, Cuizhi
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2023, 25 (03): : 673 - 684
  • [4] Methylation detection of circulating tumor cell miR-486-5p/miR-34c-5p in the progression of colorectal cancer
    Guolei Li
    Xuhua Hu
    Guiying Wang
    Cuizhi Geng
    Clinical and Translational Oncology, 2023, 25 : 673 - 684
  • [5] Downregulation of miR-486-5p contributes to tumor progression and metastasis by targeting protumorigenic ARHGAP5 in lung cancer
    J Wang
    X Tian
    R Han
    X Zhang
    X Wang
    H Shen
    L Xue
    Y Liu
    X Yan
    J Shen
    K Mannoor
    J Deepak
    J M Donahue
    S A Stass
    L Xing
    F Jiang
    Oncogene, 2014, 33 : 1181 - 1189
  • [6] Downregulation of miR-486-5p Enhances the Anti-Tumor Effect of 5-Fluorouracil on Pancreatic Cancer Cells
    Wang, Wei
    Liu, Bowei
    Sun, Suofeng
    Lan, Ling
    Chen, Yu
    Han, Shuangyin
    Li, Xiuling
    Li, Zhaoshen
    ONCOTARGETS AND THERAPY, 2020, 13 : 1649 - 1659
  • [7] miR-486-5p expression is regulated by DNA methylation in osteosarcoma
    Namlos, Heidi M.
    Skarn, Magne
    Ahmed, Deeqa
    Grad, Iwona
    Andresen, Kim
    Kresse, Stine H.
    Munthe, Else
    Serra, Massimo
    Scotlandi, Katia
    Llombart-Bosch, Antonio
    Myklebost, Ola
    Lind, Guro E.
    Meza-Zepeda, Leonardo A.
    BMC GENOMICS, 2022, 23 (01)
  • [8] miR-486-5p expression is regulated by DNA methylation in osteosarcoma
    Heidi M. Namløs
    Magne Skårn
    Deeqa Ahmed
    Iwona Grad
    Kim Andresen
    Stine H. Kresse
    Else Munthe
    Massimo Serra
    Katia Scotlandi
    Antonio Llombart-Bosch
    Ola Myklebost
    Guro E. Lind
    Leonardo A. Meza-Zepeda
    BMC Genomics, 23
  • [9] miR-486-5p: A Prognostic Biomarker for Chronic Myeloid Leukemia
    Ninawe, Anupama
    Guru, Sameer Ahmad
    Yadav, Prasant
    Masroor, Mirza
    Samadhiya, Amit
    Bhutani, Namrata
    Gupta, Naresh
    Gupta, Richa
    Saxena, Alpana
    ACS OMEGA, 2021, 6 (11): : 7711 - 7718
  • [10] Downregulation of miR-486-5p contributes to tumor progression and metastasis by targeting protumorigenic ARHGAP5 in lung cancer
    Wang, J.
    Tian, X.
    Han, R.
    Zhang, X.
    Wang, X.
    Shen, H.
    Xue, L.
    Liu, Y.
    Yan, X.
    Shen, J.
    Mannoor, K.
    Deepak, J.
    Donahue, J. M.
    Stass, S. A.
    Xing, L.
    Jiang, F.
    ONCOGENE, 2014, 33 (09) : 1181 - 1189